{"organizations": [], "uuid": "3a0d978c4dd2a4834af68018ed13226bb9d9b274", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-celgene-says-entered-into-settleme/brief-celgene-says-entered-into-settlement-with-actavis-idUSFWN1PL16A", "country": "US", "domain_rank": 408, "title": "BRIEF-Celgene Says Entered Into Settlement With Actavis​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-27T00:35:00.000+02:00", "replies_count": 0, "uuid": "3a0d978c4dd2a4834af68018ed13226bb9d9b274"}, "author": "", "url": "https://www.reuters.com/article/brief-celgene-says-entered-into-settleme/brief-celgene-says-entered-into-settlement-with-actavis-idUSFWN1PL16A", "ord_in_thread": 0, "title": "BRIEF-Celgene Says Entered Into Settlement With Actavis​", "locations": [], "entities": {"persons": [], "locations": [{"name": "abraxane", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "celgene corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "celgene", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 26, 2018 / 10:37 PM / in 20 minutes BRIEF-Celgene Says Entered Into Settlement With Actavis​ Reuters Staff 1 Min Read \nJan 26 (Reuters) - Celgene Corp: \n* CELGENE - ENTERED INTO SETTLEMENT WITH ACTAVIS LLC TO TERMINATE PENDING PATENT LITIGATION, IPR CHALLENGES RELATING TO CERTAIN PATENTS FOR ABRAXANE​ \n* CELGENE - TO GIVE ACTAVIS LICENSE TO PATENTS TO MANUFACTURE, SELL GENERIC PACLITAXEL PROTEIN-BOUND PARTICLES IN U.S. FROM MARCH 31, 2022 Source text - bit.ly/2EcZicz Further company coverage:", "external_links": [], "published": "2018-01-27T00:35:00.000+02:00", "crawled": "2018-01-27T00:54:44.029+02:00", "highlightTitle": ""}